Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Member Companies of the Opioid PMR Consortium
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02741076CT.gov Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain | — | Terminated | — | — | — |
NCT01595867CT.gov Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opioid Abuse
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nepenthe (this asset) | Member Companies of the Opioid PMR Consortium | Approved | BB · 71 |
| Oxycodone | Member Companies of the Opioid PMR Consortium | P4 | BB |
| Tizanidine | Stanford University | P3 | B |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Medical University of South Carolina | P2 | B |
| Oxymorphone Cii | Member Companies of the Opioid PMR Consortium | P4 | B |
| Duloxetine | Scripps Health | P2 | CCC |
| Marcaine | University of Alabama at Birmingham | Early P1 | CCC |
| Naltrexone | Pfizer | P1 | CC |
Other indications for Nepenthe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nepenthe in Opioid Abuse. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nepenthe-opioid-abuse
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →